Michael Friedman

810 total citations · 2 hit papers
8 papers, 564 citations indexed

About

Michael Friedman is a scholar working on Oncology, Organic Chemistry and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Michael Friedman has authored 8 papers receiving a total of 564 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Oncology, 4 papers in Organic Chemistry and 3 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Michael Friedman's work include Synthesis and biological activity (3 papers), Cytokine Signaling Pathways and Interactions (3 papers) and Monoclonal and Polyclonal Antibodies Research (2 papers). Michael Friedman is often cited by papers focused on Synthesis and biological activity (3 papers), Cytokine Signaling Pathways and Interactions (3 papers) and Monoclonal and Polyclonal Antibodies Research (2 papers). Michael Friedman collaborates with scholars based in United States, United Kingdom and Czechia. Michael Friedman's co-authors include M.A. Argiriadi, Neil Wishart, Jonathan S. George, William T. Beaver, Dennis B. Gillings, Robert J. Padley, Matthew Rosebraugh, Heidi S. Camp, Andrew J. Long and Julie Parmentier and has published in prestigious journals such as Journal of Medicinal Chemistry, Clinical Pharmacology & Therapeutics and Cancer Discovery.

In The Last Decade

Michael Friedman

8 papers receiving 549 citations

Hit Papers

In vitro and in vivo characterization of the JAK1 selecti... 2018 2026 2020 2023 2018 2024 50 100 150 200 250
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494)
    2018 276 citations Julie Parmentier, J W Voss et al. BMC Rheumatology profile →
  2. Senescent CAFs Mediate Immunosuppression and Drive Breast Cancer Progression
    2024 75 citations Jiayu Ye, John Baer et al. Cancer Discovery profile →

Peers

Michael Friedman
John Dulos Netherlands
Urmi Dhagat Australia
Anastasia Parton Switzerland
Nigel D. Staite United States
Ying Jin China
Tatjana Samardžić Czechia
Yuka Sasakawa Japan
Shaobo Yang China
R Z Arzoomanian United States
Thomas K. Barthel United States
John Dulos Netherlands
Michael Friedman
Citations per year, relative to Michael Friedman Michael Friedman (= 1×) peers John Dulos

Countries citing papers authored by Michael Friedman

Since Specialization
Citations

This map shows the geographic impact of Michael Friedman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Friedman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Friedman more than expected).

Fields of papers citing papers by Michael Friedman

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Friedman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Friedman. The network helps show where Michael Friedman may publish in the future.

Co-authorship network of co-authors of Michael Friedman

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Friedman. A scholar is included among the top collaborators of Michael Friedman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Friedman. Michael Friedman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

8 of 8 papers shown
1.
Ye, Jiayu, John Baer, Douglas V. Faget, et al.. (2024). Senescent CAFs Mediate Immunosuppression and Drive Breast Cancer Progression. Cancer Discovery. 14(7). 1302–1323. 75 indexed citations breakdown →
2.
Vasudevan, Anil, M.A. Argiriadi, Aleksandra Baranczak, et al.. (2019). Covalent binders in drug discovery. Progress in medicinal chemistry. 58. 1–62. 31 indexed citations
3.
Parmentier, Julie, J W Voss, Candace Graff, et al.. (2018). In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494). BMC Rheumatology. 2(1). 23–23. 276 indexed citations breakdown →
4.
Breinlinger, Eric C., Michael Friedman, Jianfei Wang, et al.. (2014). Discovery of Selective and Orally Bioavailable Protein Kinase Cθ (PKCθ) Inhibitors from a Fragment Hit. Journal of Medicinal Chemistry. 58(1). 222–236. 33 indexed citations
5.
Edmunds, Jeremy J., Anna Ericsson, Kristine E. Frank, et al.. (2012). Design and synthesis of tricyclic cores for kinase inhibition. Bioorganic & Medicinal Chemistry Letters. 23(3). 693–698. 18 indexed citations
6.
Cusack, Kevin P., Hamish Allen, Anca Clabbers, et al.. (2009). Identification of a selective thieno[2,3-c]pyridine inhibitor of COT kinase and TNF-α production. Bioorganic & Medicinal Chemistry Letters. 19(6). 1722–1725. 22 indexed citations
7.
Friedman, Michael, et al.. (2002). Effects of Sildenafil Citrate on Optical Properties of the Eye. 43(13). 3250–3250. 2 indexed citations
8.
Friedman, Michael, et al.. (1994). Caffeine as an analgesic adjuvant in tension headache. Clinical Pharmacology & Therapeutics. 56(5). 576–586. 107 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by John Dulos Breakdown of academic impact, for papers by Urmi Dhagat Breakdown of academic impact, for papers by Anastasia Parton Breakdown of academic impact, for papers by Nigel D. Staite Breakdown of academic impact, for papers by Ying Jin Breakdown of academic impact, for papers by Tatjana Samardžić Breakdown of academic impact, for papers by Yuka Sasakawa Breakdown of academic impact, for papers by Shaobo Yang Breakdown of academic impact, for papers by R Z Arzoomanian Breakdown of academic impact, for papers by Thomas K. Barthel
Rankless by CCL
2026